Daiichi Sankyo Company, Limited

Report azionario TSE:4568

Capitalizzazione di mercato: JP¥5.2t

Daiichi Sankyo Company Crescita futura

Criteri Future verificati 3/6

Daiichi Sankyo Company prevede che gli utili e i ricavi cresceranno rispettivamente di 13.1% e 7.2% all'anno. Si prevede che l'EPS crescerà di 13% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 17.3% in 3 anni.

Informazioni chiave

13.1%

Tasso di crescita degli utili

13.01%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili12.4%
Tasso di crescita dei ricavi7.2%
Rendimento futuro del capitale proprio17.27%
Copertura analitica

Good

Ultimo aggiornamento23 Aug 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • May 13

Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...
Articolo di analisi • Feb 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...
Articolo di analisi • Nov 04

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...

Recent updates

Aggiornamento narrativa • Aug 14

4568: Global Oncology Approvals And Partnerships Will Support Future Upside Potential

Analysts have trimmed their 12 month price target for Daiichi Sankyo Company from ¥5,500 to ¥5,200, reflecting updated assumptions around slightly lower revenue growth, a modestly higher discount rate and a marginally different long term profit margin and P/E profile. What's in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 revenue growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.
Articolo di analisi • Aug 10

Earnings Troubles May Signal Larger Issues for Daiichi Sankyo Company (TSE:4568) Shareholders

The market wasn't impressed with the soft earnings from Daiichi Sankyo Company, Limited ( TSE:4568 ) recently. We did...
Aggiornamento narrativa • Jul 31

4568: Oncology Approvals And Guidance Upgrades Will Drive Future Upside

Analysts have trimmed their price target for Daiichi Sankyo Company to around ¥4,146 from roughly ¥4,235, reflecting slightly softer assumptions for revenue growth, profit margins and future P/E multiples. What’s in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.
Aggiornamento narrativa • Jul 14

4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential

Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Aggiornamento narrativa • Jun 30

4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating

Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Aggiornamento narrativa • Jun 16

4568: Oncology Biomarker Advances And Pipeline Approvals Will Drive Future Upside

Analysts have reduced their fair value estimate for Daiichi Sankyo Company from ¥4,736.88 to ¥4,234.71, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Leica Biosystems expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and AI powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non small cell lung cancer, building on AstraZeneca’s computational pathology algorithm and Leica’s digital pathology platform for research use only.
Aggiornamento narrativa • Jun 01

4568: Oncology Pipeline Progress And Measured Outlook Will Support Future Market Rating

Analysts have trimmed their price target for Daiichi Sankyo Company from about ¥3,065 to around ¥2,846. This reflects updated assumptions for slightly lower revenue growth, a reduced profit margin, a modestly higher discount rate, and a small adjustment to future P/E expectations.
Articolo di analisi • May 13

Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next

It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...
Aggiornamento narrativa • May 11

4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential

Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.
Aggiornamento narrativa • Apr 23

4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating

Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).
Aggiornamento narrativa • Apr 08

4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential

Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).
Aggiornamento narrativa • Mar 25

4568: Oncology Pipeline Progress Will Drive Further Upside For Shares

Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).
Aggiornamento narrativa • Mar 11

4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential

Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).
Aggiornamento narrativa • Feb 25

4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares

Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).
Aggiornamento narrativa • Feb 10

4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating

Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).
Articolo di analisi • Feb 08

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00

Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...
Articolo di analisi • Feb 06

There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings

Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...
Articolo di analisi • Feb 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...
Aggiornamento narrativa • Jan 26

4568: Oncology Approvals And Trials Will Drive Future Upside Potential

Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.
Articolo di analisi • Jan 23

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00

The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...
Aggiornamento narrativa • Jan 12

4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside

Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).
Articolo di analisi • Jan 09

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00

Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...
Aggiornamento narrativa • Dec 27

4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside

Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).
Articolo di analisi • Dec 25

Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00

The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...
Aggiornamento narrativa • Dec 13

4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside

Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.
Articolo di analisi • Dec 11

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00

Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...
Aggiornamento narrativa • Nov 25

4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares

Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.
Articolo di analisi • Nov 04

Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year

Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...
Aggiornamento narrativa • Oct 22

Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks

Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.
Aggiornamento narrativa • Oct 08

Global Aging And ADC Pipelines Will Expand Oncology Markets

Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.
Articolo di analisi • Sep 21

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...
Articolo di analisi • Sep 05

Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's

Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...
Aggiornamento narrativa • Sep 04

Global Aging And ADC Pipelines Will Expand Oncology Markets

With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.

Previsioni di crescita degli utili e dei ricavi

TSE:4568 - Stime future degli analisti e dati finanziari passati (JPY Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/20292,665,656335,021218,873341,95015
3/31/20282,412,874344,206236,062377,22216
3/31/20272,357,304271,121433,612274,50013
6/30/20262,223,188243,011-21,190134,554N/A
3/31/20262,123,045259,874-71,34777,655N/A
12/31/20252,052,148304,599-53,335123,862N/A
9/30/20251,978,882279,895-68,785102,085N/A
6/30/20251,924,678295,873-64,677127,317N/A
3/31/20251,886,256295,756-134,03053,842N/A
12/31/20241,795,986245,770-162,48711,692N/A
9/30/20241,758,071250,400417,387587,088N/A
6/30/20241,687,028229,101407,158535,454N/A
3/31/20241,601,688200,731476,467599,258N/A
12/31/20231,503,471186,052509,483601,669N/A
9/30/20231,397,025147,885-79,5814,025N/A
6/30/20231,348,996147,35015,14989,040N/A
3/31/20231,278,478109,18847,148114,514N/A
12/31/20221,182,20159,35452,831120,225N/A
9/30/20221,122,72462,81685,820153,864N/A
6/30/20221,061,14050,60374,484148,554N/A
3/31/20221,044,89266,97262,544139,226N/A
12/31/20211,034,69294,47091,294161,092N/A
9/30/20211,012,31386,75652,721111,874N/A
6/30/2021989,63879,32158,547106,238N/A
3/31/2021962,51675,958128,114192,207N/A
12/31/2020963,55270,599123,806188,054N/A
9/30/2020982,388116,315132,076206,119N/A
6/30/2020969,501117,58496,878174,904N/A
3/31/2020981,793129,074N/A196,601N/A
12/31/2019983,669148,891N/A212,138N/A
9/30/2019962,440113,821N/A187,666N/A
6/30/2019953,219112,805N/A181,424N/A
3/31/2019929,71793,409N/A92,033N/A
12/31/2018922,22866,479N/A85,284N/A
9/30/2018937,64870,018N/A97,072N/A
6/30/2018946,82955,081N/A96,957N/A
3/31/2018960,19560,282N/A108,439N/A
12/31/2017961,76637,887N/A99,826N/A
9/30/2017966,50938,758N/A83,608N/A
6/30/2017953,25552,017N/A102,946N/A
3/31/2017955,12453,466N/A136,234N/A
12/31/2016962,29659,736N/A161,540N/A
9/30/2016965,68160,572N/A184,039N/A
6/30/2016989,00177,951N/A181,513N/A
3/31/2016986,44682,282N/A174,281N/A
12/31/2015839,75955,256N/A139,346N/A
9/30/2015872,74467,132N/A146,907N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 4568 ( 13.1% all'anno) è superiore al tasso di risparmio ( 0.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 4568 ( 13.1% all'anno) cresceranno più rapidamente del mercato JP ( 8.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 4568 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 4568 ( 7.2% all'anno) crescerà più rapidamente del mercato JP ( 6.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4568 ( 7.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 4568 sarà basso tra 3 anni ( 17.3 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/24 16:19
Prezzo dell'azione a fine giornata2026/08/24 00:00
Utili2026/06/30
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Daiichi Sankyo Company, Limited è coperta da 28 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research